Nakayama H - Search Results

1

Dasatinib-Associated Creatine Kinase Level Elevation.

Nakayama H, Iizuka H, Kato T, Usuki K. Nakayama H, et al. Am J Ther. 2022 Nov-Dec 01;29(6):e690-e694. doi: 10.1097/MJT.0000000000001289. Epub 2020 Dec 26. Am J Ther. 2022. PMID: 33395064 No abstract available.

2

Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Nakayama H, Usuki K, Echizen H, Ogawa R, Orii T. Nakayama H, et al. Biol Pharm Bull. 2016;39(2):285-8. doi: 10.1248/bpb.b15-00703. Biol Pharm Bull. 2016. PMID: 26830487 Free article.

3

Induration at Injection or Infusion Site May Reduce Bioavailability of Parenteral Phenobarbital Administration.

Nakayama H, Echizen H, Ogawa R, Akabane A, Kato T, Orii T. Nakayama H, et al. Ther Drug Monit. 2017 Jun;39(3):297-302. doi: 10.1097/FTD.0000000000000391. Ther Drug Monit. 2017. PMID: 28328763

4

Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life.

Nakayama H, Echizen H, Ogawa R, Orii T, Kato T. Nakayama H, et al. Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):77-82. doi: 10.1007/s13318-018-0495-5. Eur J Drug Metab Pharmacokinet. 2019. PMID: 30027304

5

Amikacin Pharmacokinetics in Terminal Stage of Hematological Malignancy.

Nakayama H, Suzuki M, Usuki K, Kato T. Nakayama H, et al. Ther Drug Monit. 2019 Aug;41(4):533-537. doi: 10.1097/FTD.0000000000000621. Ther Drug Monit. 2019. PMID: 30817701

6

Vancomycin Pharmacokinetics in Patients with Advanced Cancer Near End of Life.

Nakayama H, Suzuki M, Kato T, Echizen H. Nakayama H, et al. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):837-843. doi: 10.1007/s13318-019-00564-w. Eur J Drug Metab Pharmacokinet. 2019. PMID: 31154618

7

Does Diarrhea Influence Plasma Voriconazole Concentration?

Nakayama H, Usuki K, Hanada K, Orii T, Kato T. Nakayama H, et al. Ther Drug Monit. 2020 Apr;42(2):341-344. doi: 10.1097/FTD.0000000000000730. Ther Drug Monit. 2020. PMID: 31972774 No abstract available.

8

Is higher lymphocyte count a potential strategy for preventing chronic kidney disease in patients receiving long-term dasatinib treatment?

Nakayama H, Iizuka H, Kato T, Usuki K. Nakayama H, et al. J Pharm Health Care Sci. 2023 Jan 23;9(1):4. doi: 10.1186/s40780-022-00270-x. J Pharm Health Care Sci. 2023. PMID: 36691104 Free PMC article.

9

Abrupt increased serum creatinine in a hyperferritinemia patient treated with deferoxamine after cord blood transplantation: a case report with literature review.

Nakayama H, Kamoda Y, Tanuma M, Kato T, Usuki K. Nakayama H, et al. J Pharm Health Care Sci. 2023 Jun 1;9(1):18. doi: 10.1186/s40780-023-00287-w. J Pharm Health Care Sci. 2023. PMID: 37259120 Free PMC article.

10

Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks.

Nakayama H, Echizen H, Tanaka M, Sato M, Orii T. Nakayama H, et al. Ther Drug Monit. 2008 Feb;30(1):103-7. doi: 10.1097/FTD.0b013e318164f781. Ther Drug Monit. 2008. PMID: 18223471

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,267 results

Search Page

Filters